FR20C1014I2 - Traitement de troubles du cycle sommeil-eveil - Google Patents

Traitement de troubles du cycle sommeil-eveil

Info

Publication number
FR20C1014I2
FR20C1014I2 FR20C1014C FR20C1014C FR20C1014I2 FR 20C1014 I2 FR20C1014 I2 FR 20C1014I2 FR 20C1014 C FR20C1014 C FR 20C1014C FR 20C1014 C FR20C1014 C FR 20C1014C FR 20C1014 I2 FR20C1014 I2 FR 20C1014I2
Authority
FR
France
Prior art keywords
sleep
treatment
wake cycle
cycle disorders
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1014C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of FR20C1014I1 publication Critical patent/FR20C1014I1/fr
Application granted granted Critical
Publication of FR20C1014I2 publication Critical patent/FR20C1014I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR20C1014C 2005-06-08 2020-04-16 Traitement de troubles du cycle sommeil-eveil Active FR20C1014I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
PCT/US2006/022407 WO2006133393A1 (en) 2005-06-08 2006-06-07 Treatment of sleep-wake disorders

Publications (2)

Publication Number Publication Date
FR20C1014I1 FR20C1014I1 (en:Method) 2020-06-12
FR20C1014I2 true FR20C1014I2 (fr) 2021-04-23

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1014C Active FR20C1014I2 (fr) 2005-06-08 2020-04-16 Traitement de troubles du cycle sommeil-eveil

Country Status (16)

Country Link
US (8) US8440715B2 (en:Method)
EP (1) EP1890684B1 (en:Method)
JP (1) JP5024635B2 (en:Method)
KR (1) KR101335941B1 (en:Method)
CN (1) CN101217949B (en:Method)
AU (1) AU2006254899B2 (en:Method)
BR (1) BRPI0613697A2 (en:Method)
CA (1) CA2611713C (en:Method)
DK (1) DK1890684T3 (en:Method)
ES (1) ES2435403T3 (en:Method)
FR (1) FR20C1014I2 (en:Method)
NL (1) NL301037I2 (en:Method)
PL (1) PL1890684T3 (en:Method)
RU (1) RU2417077C2 (en:Method)
TW (2) TW201328689A (en:Method)
WO (1) WO2006133393A1 (en:Method)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133393A1 (en) * 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders
CA2612672C (en) * 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
CN102481274A (zh) * 2009-06-22 2012-05-30 爱思开生物制药株式会社 治疗或预防疲劳的方法
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8927602B2 (en) * 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
WO2011055965A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
RU2019114940A (ru) 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
TW201919605A (zh) 2013-07-18 2019-06-01 南韓商愛思開生物製藥股份有限公司 肥胖之治療
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016061488A1 (en) * 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CA3036071A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
JP2020528075A (ja) * 2017-06-02 2020-09-17 ジャズ ファーマシューティカルズ アイルランド リミテッド 過度の眠気を処置するための方法および組成物
WO2019027941A1 (en) * 2017-07-31 2019-02-07 Jazz Pharmaceuticals International Iii Limited CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
EP4615426A1 (en) * 2022-11-07 2025-09-17 Axsome Therapeutics Compositions and methods for treating insomnia
EP4626417A1 (en) * 2022-11-30 2025-10-08 Axsome Therapeutics Methods and compositions for improving driving performance
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) * 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) * 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
EP1408953B1 (en) * 2001-02-27 2006-04-26 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
ES2262826T3 (es) * 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato en la prevencion o el tratamiento de transtornos de ansiedad.
CA2439478C (en) * 2001-02-27 2010-05-18 Carlos R. Plata-Salaman Carbamate compounds for use in preventing or treating movement disorders
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
WO2006133393A1 (en) * 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
EA019935B1 (ru) 2005-07-26 2014-07-30 Янссен Фармацевтика Н.В. Способы лечения алкогольной абстиненции
EA200970377A1 (ru) 2006-10-13 2009-10-30 Янссен Фармацевтика Нв Композиции фенилалкиламинокарбамата
CN102481274A (zh) 2009-06-22 2012-05-30 爱思开生物制药株式会社 治疗或预防疲劳的方法
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
WO2011055965A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
RU2019114940A (ru) * 2013-03-13 2019-06-28 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии

Also Published As

Publication number Publication date
KR101335941B1 (ko) 2013-12-04
US9604917B2 (en) 2017-03-28
TWI419681B (zh) 2013-12-21
JP5024635B2 (ja) 2012-09-12
DK1890684T3 (da) 2013-10-14
RU2008100019A (ru) 2009-07-20
US10351517B2 (en) 2019-07-16
US20210078943A1 (en) 2021-03-18
US20190367448A1 (en) 2019-12-05
TW200716084A (en) 2007-05-01
AU2006254899A1 (en) 2006-12-14
US20250109099A1 (en) 2025-04-03
US8877806B2 (en) 2014-11-04
CA2611713C (en) 2013-10-01
EP1890684A1 (en) 2008-02-27
WO2006133393A1 (en) 2006-12-14
US8440715B2 (en) 2013-05-14
PL1890684T3 (pl) 2014-05-30
CN101217949B (zh) 2012-10-17
JP2008545795A (ja) 2008-12-18
KR20080035565A (ko) 2008-04-23
CN101217949A (zh) 2008-07-09
FR20C1014I1 (en:Method) 2020-06-12
NL301037I1 (en:Method) 2020-04-01
US20090312416A1 (en) 2009-12-17
US11753368B2 (en) 2023-09-12
TW201328689A (zh) 2013-07-16
US20240239740A1 (en) 2024-07-18
US20140350098A1 (en) 2014-11-27
US20170158622A1 (en) 2017-06-08
RU2417077C2 (ru) 2011-04-27
US12209059B2 (en) 2025-01-28
AU2006254899B2 (en) 2011-11-24
BRPI0613697A2 (pt) 2011-01-25
NL301037I2 (nl) 2020-05-12
US20130137764A1 (en) 2013-05-30
EP1890684B1 (en) 2013-08-14
CA2611713A1 (en) 2006-12-14
ES2435403T3 (es) 2013-12-19

Similar Documents

Publication Publication Date Title
FR20C1014I2 (fr) Traitement de troubles du cycle sommeil-eveil
EP2056673A4 (en) COMBINATION TREATMENT FOR METABOLISM DISEASES
EP1885388A4 (en) TREATMENT AND ASSESSMENT OF INFLAMMATORY DISEASES
EP1968582A4 (en) TREATMENT OF CUTTAN T CELL LYMPHOMA
EP1908486A4 (en) DIALYSIS THERAPY DEVICE
EP1870051A4 (en) MEDICAL THERAPY DEVICE
EP1982660A4 (en) TREATMENT ENDOSCOPE
EP2046349A4 (en) TREATMENT OF EXCESSIVE NEOVASCULARIZATION
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP2001461A4 (en) COMBINATION TREATMENT FOR METABOLISM DISEASES
EP1755584A4 (en) Treatment of myopia
EP1744751A4 (en) METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
EP1993528A4 (en) TREATMENT MODULES FOR AUTOIMMUNE DISEASES
EP1898930A4 (en) Treatment of inflammatory conditions
EP2323641A4 (en) NYASOL AND ANALOGUE THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES
EP1861126A4 (en) TREATMENT OF PROTEIN REMOVAL TROUBLES
FR2912833B1 (fr) Panneau pour le traitement acoustique
EP2176283A4 (en) METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES
EP2303184A4 (en) COMBINATION TREATMENT OF GREEN STAR
EP2032987A4 (en) PHARMACOLOGICAL TREATMENT OF COGNITIVE IMPAIRMENT
EP2028937A4 (en) TREATMENT WITH MELATONE IN AGONISTS
EP2247297A4 (en) THERAPEUTIC TREATMENT OF LUNG DISEASES
EP2056858A4 (en) TREATMENT OF LUNG DISEASES
EP2368499A4 (en) TREATMENT INSTRUMENT
BRPI0715728A8 (pt) tratamento de distúrbios cartilaginosos